Shots:

• CPSC has dosed its first patients in a Chinese bridging study assessing Copiktra in patients with r/r FL
• In Sept’2018- the companies signed an exclusive licensing agreement which allows CPSC to develop & commercialize Verastem’ Copiktra for all oncology indications in China. The study is expected to serve as a bridging study based on the safety & efficacy in Verastem’s P-II DYNAMO study
• Copiktra is a PI3K inhibitor- the first approved dual inhibitor of PI3K-delta and PI3K-gamma in the US and has received the FDA’s approval for r/r CLL/SLL following two prior therapies in Sept’2018

Click here to­ read full press release/ article | Ref: Business wire | Image: Verastem